Good morning, everyone, and how are you today? We are doing just fine, thank you, as a warm and shiny sun envelopes the Pharmalot campus. Moreover, a calming quiet has taken hold, now that the short people have left for their respective destinations — the local schoolhouse and gainful employment. All of which means we have an opportunity to catch up on our to-do list and dig in for another busy day. No doubt, you may relate. So here are a few items of interest to get you started. Hope all goes well today and, as always, do keep in touch …

AstraZeneca (AZN) has suspended investments in the U.K. due to the lack of clarity over the country’s looming departure from the European Union, Le Monde says. “If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” non-executive chairman Leif Johansson tells the paper. The drug maker has already spent more than $50 million stockpiling medicines in the U.K. and continental Europe to prevent supply disruptions if the two sides fail to reach a withdrawal agreement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy